Aptevo Therapeutics Inc. (APVO): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of APVO were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
No APVO insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
APVO short interest
Low short interest. 4.0% of APVO shares are sold short: about 1 share in 25. Over the last 12 reports the number of shares short went down 19%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 71,260 APVO shares were sold short, 4.0% of the shares outstanding, down 26.2% from the report before. At the average daily volume of 36,885 shares, buying them all back would take about 1.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 71,260 | 3.95% | -26% | 36,885 | 1.9 |
| Oct 15, 2026 | 96,527 | 5.36% | -19% | 50,101 | 1.9 |
| Sep 30, 2026 | 119,457 | 6.63% | -36% | 69,825 | 1.7 |
| Sep 15, 2026 | 187,942 | 10.43% | +59% | 336,643 | 1.0 |
| Aug 31, 2026 | 118,188 | 6.56% | +45% | 61,195 | 1.9 |
| Aug 14, 2026 | 81,745 | 4.54% | -7% | 33,741 | 2.4 |
| Jul 31, 2026 | 87,627 | 7.42% | -36% | 19,324 | 4.5 |
| Jul 15, 2026 | 137,249 | 11.61% | +73% | 165,612 | 1.0 |
| Jun 30, 2026 | 79,436 | 6.72% | -1% | 23,282 | 3.4 |
| Jun 15, 2026 | 80,080 | 6.78% | -0% | 36,881 | 2.2 |
| May 29, 2026 | 80,160 | 6.78% | -9% | 29,937 | 2.7 |
| May 15, 2026 | 87,845 | 7.43% | -5% | 58,805 | 1.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Aptevo Therapeutics company events
Aptevo Therapeutics filed 23 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 9, 2026.
- Nov 9, 2026AnnouncementAptevo Therapeutics Inc. issued a press release announcing that on November 7, 2026, the Company presented new preclinical data from its next-generation multispecific platform at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting. Filing
- Nov 5, 2026AnnouncementAptevo Therapeutics Inc. issued a press release announcing an important clinical development milestone for mipletamig: a substantial reduction in infusion-related reactions (IRRs) following successive refinements to its priming-dose regimen. Filing
- Nov 2, 2026AnnouncementAptevo Therapeutics Inc. filed with the Securities and Exchange Commission (the “SEC’) a prospectus supplement (the “Prospectus Supplement” and collectively with the Prior Prospectus (as defined below), the “Prospectus”) under the Company’s effective registration statement on Form S-3 (File No.… Filing
- Oct 26, 2026AnnouncementAptevo Therapeutics Inc. issued a press release announcing ten patients with newly diagnosed acute myeloid leukemia (AML) have advanced to allogeneic stem cell transplant following treatment with mipletamig in combination with venetoclax and azacitidine. Filing
- Oct 23, 2026AgreementAptevo Therapeutics Inc. entered into Amendment No. 6 to the Rights Agreement, dated as of November 8, 2020, between the Company and Broadridge Corporate Issuer Solutions, LLC, as rights agent (as amended and/or restated from time to time, the “Rights Agreement”). Filing
- Oct 14, 2026AnnouncementAptevo Therapeutics Inc. issued a press release announcing its multispecific platform will be presented at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, being held November 4–8, 2026, at the Phoenix Convention Center in Phoenix, Arizona. Filing
- Sep 24, 2026AnnouncementAptevo Therapeutics Inc. issued a press release announcing progress in its next-generation trispecific programs. Filing
- Sep 23, 2026VoteReported shareholder vote results. Filing
- Sep 3, 2026AnnouncementAptevo Therapeutics Inc. issued a press release announcing a 93% clinical benefit rate with its mipletamig triplet in evaluable frontline acute myeloid leukemia (AML) patients with TP53 mutations, one of the most difficult-to-treat forms of the disease and a patient population that has historically… Filing
- Aug 21, 2026VoteReported shareholder vote results. Filing
- Aug 14, 2026ResultsReleased financial results. Filing
- Aug 13, 2026AgreementAptevo Therapeutics Inc. entered into Warrant Inducement and Reload Letters with certain holders of the Company’s common stock purchase warrants, issued on June 20, 2025, on April 3, 2025 and on December 12, 2024 (the “December 2024 Warrants” and together with the June 2025 Warrants and the April… Filing
- Jul 27, 2026AnnouncementAptevo Therapeutics Inc. announced a new solid tumor strategy and the filing of a patent application covering a proprietary Nectin-4 x PD-L1 dual-targeting backbone. Filing
- Jun 30, 2026AgreementAptevo Therapeutics Inc. entered into a Grant Award Agreement with the Andy Hill Cancer Research Endowment (CARE) Fund, a Washington State–established public research endowment. Filing
- May 27, 2026AgreementAptevo Research and Development LLC, a subsidiary of Aptevo Therapeutics Inc., and Niowave, Inc. entered into a collaboration agreement to collaborate on the development of a potential human therapeutic product incorporating Aptevo’s proprietary molecules (including APVO455) and Niowave’s… Filing
- May 13, 2026ResultsReleased financial results. Filing
- May 6, 2026AnnouncementAptevo Therapeutics Inc. issued a press release announcing new clinical results from its RAINIER frontline acute myeloid leukemia (AML) trial. Filing
- Mar 26, 2026ResultsReleased financial results. Filing
- Mar 11, 2026AnnouncementAptevo Therapeutics Inc. issued a press release announcing new interim data for mipletamig in combination with venetoclax and azacitidine in newly diagnosed acute myeloid leukemia (AML) patients. Filing
- Feb 19, 2026VoteReported shareholder vote results. Filing
- Feb 3, 2026LeadershipMarvin L. White notified Aptevo Therapeutics Inc. of his intent to retire as the Company’s President and Chief Executive Officer, effective as of April 1, 2026. Filing
- Jan 9, 2026AgreementAptevo Therapeutics Inc. entered into a Standby Equity Purchase Agreement with YA II PN, LTD., a Cayman Islands exempt limited company. Filing
- Dec 29, 2025RulesChanged its bylaws or articles. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Aptevo Therapeutics financials
Famous investors that hold APVO
1 of the 50 well-known investors we track reported holding APVO in their latest 13F filing. The largest position is Ken Griffin's, worth $45.8K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 25,171 | $45.8K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named APVO in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | CVI Investments, Inc. | 13G/A | 4.4% |
| Nov 16, 2026 | CVI Investments, Inc. | 13G/A | 4.4% |
| Nov 12, 2026 | Ayrton Capital LLC | 13G/A | 3.7% |
| Nov 12, 2026 | Ayrton Capital LLC | 13G/A | 3.7% |
Questions about Aptevo Therapeutics Inc. (APVO) stock
Are APVO insiders buying or selling?
No APVO insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in APVO?
As of Oct 30, 2026, 71,260 APVO shares were sold short, 4.0% of the shares outstanding, down 26.2% from the report before. At the average daily volume of 36,885 shares, buying them all back would take about 1.9 trading days (days to cover). See the history.
Which famous investors hold APVO?
1 of the 50 well-known investors we track reported APVO in their latest 13F filing, including Ken Griffin. The largest position is worth $45.8K. See all holders.
Executive pay
Aptevo Therapeutics's chief executive was paid a total of $1.3M for the year ended Dec 31, 2025, up 50% from $846K the year before. In the last 12 months, Aptevo Therapeutics's executives and directors bought no stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.